Literature DB >> 8604293

Activation domains of transcription factors mediate replication dependent transcription from a minimal HIV-1 promoter.

R D Williams1, B A Lee, S P Jackson, N J Proudfoot.   

Abstract

Transcription from a minimal HIV-1 promoter containing the three Sp1 binding sites and TATA box can be activated without Tat by template DNA replication. Here we show that this activation can also be mediated by recombinant GAL4 fusion proteins containing the activation domains of Sp1, VP16 or CTF (or by full-length GAL4) targeted to the HIV-1 promoter by replacing the Sp1 sites with five GAL4 binding sites. Thus Sp1 is not unique in its ability to mediate replication activated transcription, although the degree of processivity elicited by the different activators varied significantly from strongly processive (GAL4-VP16) to relatively non-processive (GAL4-Sp1 or -CTF). Processive GAL4-VP16-activated transcription, but not efficient initiation, required multiple GAL4 binding sites. In the presence of Tat, transcription with GAL4-SP1 and GAL4-CTF was further activated (principally at the level of processivity) but GAL4-VP16-potentiated transcription was only slightly stimulated. The Tat-dependent switch from non-processive to fully processive transcription was particularly marked for GAL4-Sp1, an effect which may be relevant to the selection of Sp1 binding sites by the HIV-1 promoter.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8604293      PMCID: PMC145701          DOI: 10.1093/nar/24.4.549

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  43 in total

1.  Cell- and promoter-specific activation of transcription by DNA replication.

Authors:  D S Grass; D Read; E D Lewis; J L Manley
Journal:  Genes Dev       Date:  1987-12       Impact factor: 11.361

2.  Promoter-proximal pausing of RNA polymerase II defines a general rate-limiting step after transcription initiation.

Authors:  A Krumm; L B Hickey; M Groudine
Journal:  Genes Dev       Date:  1995-03-01       Impact factor: 11.361

3.  Deletion analysis of GAL4 defines two transcriptional activating segments.

Authors:  J Ma; M Ptashne
Journal:  Cell       Date:  1987-03-13       Impact factor: 41.582

4.  Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter.

Authors:  D A Melton; P A Krieg; M R Rebagliati; T Maniatis; K Zinn; M R Green
Journal:  Nucleic Acids Res       Date:  1984-09-25       Impact factor: 16.971

5.  DNA replication and the early to late transition in adenovirus infection.

Authors:  G P Thomas; M B Mathews
Journal:  Cell       Date:  1980-11       Impact factor: 41.582

6.  Activation of the adenovirus 2 protein IX promoter by DNA replication in a transient expression assay.

Authors:  L K Venkatesh; G Chinnadurai
Journal:  Nucleic Acids Res       Date:  1987-03-11       Impact factor: 16.971

7.  Adenovirus 2 peptide IX gene is expressed only on replicated DNA molecules.

Authors:  T Matsui; M Murayama; T Mita
Journal:  Mol Cell Biol       Date:  1986-12       Impact factor: 4.272

8.  The yeast UASG is a transcriptional enhancer in human HeLa cells in the presence of the GAL4 trans-activator.

Authors:  N Webster; J R Jin; S Green; M Hollis; P Chambon
Journal:  Cell       Date:  1988-01-29       Impact factor: 41.582

9.  cis and trans activation of globin gene transcription in transient assays.

Authors:  R Treisman; M R Green; T Maniatis
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

10.  Assembly of transfected DNA into chromatin: structural changes in the origin-promoter-enhancer region upon replication.

Authors:  S Cereghini; M Yaniv
Journal:  EMBO J       Date:  1984-06       Impact factor: 11.598

View more
  9 in total

Review 1.  Regulation of HIV-1 transcription.

Authors:  K A Roebuck; M Saifuddin
Journal:  Gene Expr       Date:  1999

2.  Expression of human endogenous retrovirus type K (HML-2) is activated by the Tat protein of HIV-1.

Authors:  Marta J Gonzalez-Hernandez; Michael D Swanson; Rafael Contreras-Galindo; Sarah Cookinham; Steven R King; Richard J Noel; Mark H Kaplan; David M Markovitz
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

3.  Interference of the simian virus 40 origin of replication by the cytomegalovirus immediate early gene enhancer: evidence for competition of active regulatory chromatin conformation in a single domain.

Authors:  P H Chen; W B Tseng; Y Chu; M T Hsu
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

4.  Transcription and polyadenylation in a short human intergenic region.

Authors:  S Brackenridge; H L Ashe; M Giacca; N J Proudfoot
Journal:  Nucleic Acids Res       Date:  1997-06-15       Impact factor: 16.971

5.  Antagonistic effects of T-Ag and VP16 reveal a role for RNA pol II elongation on alternative splicing.

Authors:  S Kadener; P Cramer; G Nogués; D Cazalla; M de la Mata; J P Fededa; S E Werbajh; A Srebrow; A R Kornblihtt
Journal:  EMBO J       Date:  2001-10-15       Impact factor: 11.598

6.  Differential in vivo activation of the class II and class III snRNA genes by the POU-specific domain of Oct-1.

Authors:  S Murphy
Journal:  Nucleic Acids Res       Date:  1997-06-01       Impact factor: 16.971

7.  Poly(A)-driven and poly(A)-assisted termination: two different modes of poly(A)-dependent transcription termination.

Authors:  G Yeung; L M Choi; L C Chao; N J Park; D Liu; A Jamil; H G Martinson
Journal:  Mol Cell Biol       Date:  1998-01       Impact factor: 4.272

8.  The sly-miR166-SlyHB module acts as a susceptibility factor during ToLCNDV infection.

Authors:  Ashish Prasad; Namisha Sharma; Oceania Chirom; Manoj Prasad
Journal:  Theor Appl Genet       Date:  2021-10-12       Impact factor: 5.699

9.  Cell-cycle dependence of transcription dominates noise in gene expression.

Authors:  C J Zopf; Katie Quinn; Joshua Zeidman; Narendra Maheshri
Journal:  PLoS Comput Biol       Date:  2013-07-25       Impact factor: 4.475

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.